Company Profile

GeneSegues Inc
Profile last edited on: 5/21/18      CAGE: 33UJ3      UEI:

Business Identifier: RNAi and DNA therapeutics for cancer and infectious diseases,
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

10285 Yellow Circle Drive
Minnetonka, MN 55343
   (612) 354-5753
Location: Single
Congr. District: 05
County: Hennepin

Public Profile

GeneSegues Therapeutics is a biopharmaceutical company specializing in the innovation of DNA and RNAi cancer therapeutics, delivered with proprietary sub-50 nanometer (s50) nanocapsule technology. The company’s lead product is GS-10, an s50-encapsulated RNAi therapeutic for the treatment of a range of solid tumor cancers including head and neck, prostate and breast and their related metastases. The firm is developing the next generation of targeted drugs for treatment of cancer and other diseases caused by the overproduction of a protein by combining innovative RNAi therapeutics with novel sub-50 nanometer capsule technology that increases the amount of RNAi drug delivered to both primary and metastatic tumors. At 20 nanometers in diameter, s50 nanocapsules are three times smaller than conventional targeted nanoparticles, allowing them to reach and attack cancerous cells where other targeted technologies cannot. This smaller size was engineered without loss of functionality. Thus, in addition to the capability to reach micro-tumors, s50 nanocapsules have active tumor targeting and high payloads of drug in each nanocapsule

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  John MacDonald -- Lead Advisor, Drug Development

  Laura Morris Brod -- CEO

  Gretchen M Unger -- Chief Scientfic Officer

  Arkadiusz Dudek -- Medical Advisor

  Mark Sorenson -- Lead Advisor, Chemistry, Manufacturing and Controls

  John F Stapleton -- Chair of the Board

  Robert Unger -- Chief Financial Officer